TY - JOUR
T1 - Inotropes in chronic beta-blocker therapy
AU - Alsagaff, Mochamad Yusuf
AU - Susanti, Melly
AU - Thaha, Mochammad
AU - Jonatan, Christian
N1 - Publisher Copyright:
© 2021 Phcogj.Com.
PY - 2021/5
Y1 - 2021/5
N2 - The increasing rate of cardiovascular disorders contributes to rising hospitalized patients receive chronic oral beta-blocker therapy. Beta-blockers remain one of the fundamental therapy for chronic heart failure. Still, their role in decompensated heart failure and severe sepsis during hospitalization is often debated and inconsistent in clinical practice. In recent years, evidence of the efficacy and clinical outcomes of beta-blockers in acute heart failure (AHF) have accumulated. Clinical research indicates that chronic beta-blockade withdrawals should be prevented, or as soon as hemodynamic stabilization and euvolemic condition are reached, it should be reinstituted. As a subset of AHF patients with low cardiac output required inotropes, the choice of proper agent is fundamental. Different inotropic agents such as inhibitors of the phosphodiesterase, levosimendan, and dobutamine also their associations with beta-blockers are discussed.
AB - The increasing rate of cardiovascular disorders contributes to rising hospitalized patients receive chronic oral beta-blocker therapy. Beta-blockers remain one of the fundamental therapy for chronic heart failure. Still, their role in decompensated heart failure and severe sepsis during hospitalization is often debated and inconsistent in clinical practice. In recent years, evidence of the efficacy and clinical outcomes of beta-blockers in acute heart failure (AHF) have accumulated. Clinical research indicates that chronic beta-blockade withdrawals should be prevented, or as soon as hemodynamic stabilization and euvolemic condition are reached, it should be reinstituted. As a subset of AHF patients with low cardiac output required inotropes, the choice of proper agent is fundamental. Different inotropic agents such as inhibitors of the phosphodiesterase, levosimendan, and dobutamine also their associations with beta-blockers are discussed.
KW - Beta-blocker
KW - Decompensated heart failure
KW - Inotropes
KW - Severe sepsis
UR - http://www.scopus.com/inward/record.url?scp=85106382821&partnerID=8YFLogxK
U2 - 10.5530/pj.2021.13.105
DO - 10.5530/pj.2021.13.105
M3 - Review article
AN - SCOPUS:85106382821
SN - 0975-3575
VL - 13
SP - 828
EP - 834
JO - Pharmacognosy Journal
JF - Pharmacognosy Journal
IS - 3
ER -